Atara CMO Joshi departs; consulting deal includes $180K milestone on tabelecleucel BLA approval

Atara Biotherapeutics, Inc.

EVP, Chief Medical Officer Dr. Joshi terminated Feb 2, 2024 as part of reduction in force.
Entered consulting agreement Feb 22, 2024: $3,000 monthly fee plus $300/hr for excess hours.
Outstanding RSU equity awards will continue vesting during consulting term.
Eligible for $180,000 payment upon FDA approval of tabelecleucel BLA.
Consulting arrangement runs through January 31, 2025.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Joshi

Executive Vice President, Chief Medical Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2024-02-02
Filed: February 23, 2024, 6:59 PM ET

the employment of the Company’s Executive Vice President, Chief Medical Officer would terminate effective as of February 2, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Joshi was terminated as Executive Vice President, Chief Medical Officer at Atara Biotherapeutics, Inc..

Action: terminated
Role: Executive Vice President, Chief Medical Officer

Exact text from the filing

the employment of the Company’s Executive Vice President, Chief Medical Officer would terminate effective as of February 2, 2024

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-019416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.